구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Taxane |
Overview Company | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Gastric Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | Deruxtecan in Patients With Previously Treated HER |
MoA Mechanism | targeting this shared pathway |
MoA Biomarker | biomarker-informed trials, rather than to identify a single preferred ICI strategy |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial.. Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter randomized controlled trial, 48 patients with… |
Clinical Safety signal | Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial.. Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter randomized controlled trial, 48 patients with… |
Clinical Selected reported efficacy | ORR 36% |
Clinical Reported ORR | 36% |
Clinical Result source | ClinicalTrials.gov NCT00462423 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00462423 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Taxane |
Overview Company | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Gastric Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | Deruxtecan in Patients With Previously Treated HER |
MoA Mechanism | targeting this shared pathway |
MoA Biomarker | biomarker-informed trials, rather than to identify a single preferred ICI strategy |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial.. Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter randomized controlled trial, 48 patients with… |
Clinical Safety signal | Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial.. Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter randomized controlled trial, 48 patients with… |
Clinical Selected reported efficacy | ORR 36% |
Clinical Reported ORR | 36% |
Clinical Result source | ClinicalTrials.gov NCT00462423 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00462423 |
추천 비교
추천 비교